Systematic review underlying new ACS guideline summarizes benefits and harms of PSA screening

Meta-analysis · Cancer · 2026-11-13. Number 1 in the UrologyWatch Top 5 for November 13, 2026.

A systematic review of 29 publications, including 23 from six randomized trials (PLCO, CAP, ERSPC, Goteborg-1, Rotterdam Pilot 1, ProScreen) and four observational studies, found PSA screening was associated with reduced incidence of advanced/metastatic disease and, in some trials, reduced prostate cancer-specific mortality, though findings on mortality were inconsistent.

Why it matters: Provides the evidence base, drawn from a systematic review of RCTs and observational studies, behind the updated ACS PSA screening guideline, useful for shared decision-making conversations.

Limitation: Findings on mortality benefit were inconsistent across trials and depended on screening protocols and populations studied.

Source: Cancer · PubMed 43018378 · DOI 10.1002/cncr.70660

The full November 13, 2026 edition · Today's urology news

Loading today's edition…